We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » New Jersey Drugmaker Hit for Litany of Issues, Including OOS Management
New Jersey Drugmaker Hit for Litany of Issues, Including OOS Management
The FDA cited Lupin’s Novel Laboratories facility in Somerset, New Jersey, for its handling of out-of-specification results and other violations observed in a Dec. 3-21, 2018 inspection.